In the CATT (Comparison of AMD Treatments Trials), which finding regarding ranibizumab versus bevacizumab for neovascular AMD was most clinically significant?
- A Bevacizumab was non-inferior to ranibizumab in visual acuity outcomes ✓
- B Ranibizumab produced significantly superior visual acuity gains at 1 year
- C Monthly ranibizumab was superior to PRN ranibizumab
- D Bevacizumab caused significantly more systemic adverse events
Correct answer: A. Bevacizumab was non-inferior to ranibizumab in visual acuity outcomes
Explanation
The CATT trial demonstrated that bevacizumab was non-inferior to ranibizumab for visual acuity outcomes at 1 and 2 years, despite bevacizumab costing approximately 40 times less per injection. Monthly treatment was superior to PRN dosing at 1 year, but this difference narrowed at 2 years. Systemic serious adverse events were slightly higher with bevacizumab but not statistically significantly different for individual adverse event categories. This trial fundamentally changed global treatment practices, establishing bevacizumab as a cost-effective alternative.
Reference: Khurana Comprehensive Ophthalmology, 7th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.